NCLAT Court IV Supplementary Cause List for March 24, 2026

The National Company Law Appellate Tribunal (NCLAT) has issued a supplementary cause list for Court IV, scheduled for March 24, 2026. The document outlines the cases to be heard, including those for judgment, and provides instructions for participating in hybrid mode video conferencing hearings.

NCLAT Chennai Daily Cause List - March 25, 2026

The National Company Law Appellate Tribunal (NCLAT) Chennai Bench has published its daily cause list for March 25, 2026. The document outlines the cases scheduled for hearing, including those for admission, stay, orders, and defective cases, indicating routine judicial proceedings.

USPTO Grants Patent for ACE Inhibitor and Blood Pressure-Lowering Agent

The USPTO has granted a patent (US12582146B2) to MARUZEN PHARMACEUTICALS CO., LTD. for an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent containing a specific compound. The patent also covers beverages and food products incorporating this compound.

USPTO Patent Grant: Topical Anti-inflammatory Composition with Zileuton

The USPTO has granted a patent (US12582598B2) to QURIENT CO., LTD. for a topical anti-inflammatory pharmaceutical composition comprising Zileuton. The patent covers the composition, its uses, and methods of preparation.

USPTO Patent Grant: B-RAF Kinase Inhibitor Solid Dispersion

The USPTO has granted a patent to BeiGene, Ltd. for a stable solid dispersion of a B-RAF kinase dimer inhibitor, Compound 1. The patent covers the composition, methods of preparation, and uses of this solid dispersion, as well as a crystalline form of Compound 1.

Moderna Cancer Vaccines Patent Grant

The USPTO has granted patent US12582609B2 to ModernaTX, Inc. for cancer ribonucleic acid (RNA) vaccines. The patent covers cancer RNA vaccines, methods of use, and compositions. This grant is a routine notification of intellectual property protection.

Patent: ROS-detonable Nanoclusters for Anti-Restenotic Therapy

The USPTO has granted a patent (US12582613B2) for biomimetic, reactive oxygen species-detonable nanoclusters designed for anti-restenotic therapy. The technology, assigned to the University of Virginia Patent Foundation, involves nanoclusters with self-assembled cores and biomimetic membrane coatings that can deliver anti-restenotic drugs.

USPTO Patent Granted for Dissociative Disorder Treatment Methods

The USPTO has granted a patent (US12582616B2) to The Board of Trustees of the Leland Stanford Junior University for methods of treating dissociative disorders. The patent covers agents that modulate neural activity in the posteromedial cortex to treat these conditions.

USPTO Grants Patent for Bis-biguanide Compounds in Cancer Management

The USPTO has granted a patent (US12582618B2) to Emory University for bis-biguanide compounds and pharmaceutical compositions for managing cancer, particularly lung cancer. The patent covers methods of treatment and related compositions, with an effective grant date of March 24, 2026.

Bifunctional compounds for degrading BTK via ubiquitin pathway

The USPTO has granted patent US12582722B2 to Nurix Therapeutics, Inc. for bifunctional compounds designed to degrade Bruton's tyrosine kinase (BTK) through the ubiquitin proteolytic pathway. The patent covers novel compounds and pharmaceutical compositions for treating various diseases.